Oncopeptides Q2 2025: Another Strong Q/Q Growth and Rights Issue - Redeye

The sales number for Q2 had already been communicated and was slightly above our forecast. Expenses were in line with our forecast. Since no deal has been signed yet, the company will need liquidity to cover the coming quarters and will raise money through a rights issue.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123773/oncopeptides-q2-2025-another-strong-q-q-growth-and-rights-issue?utm_source=finwire&utm_medium=RSS